May 18, 2017 / 3:09 PM / 2 months ago

BRIEF-AB Science presents Phase 3 data for Masitinib in amyotrophic lateral sclerosis (ALS)

1 Min Read

May 18 (Reuters) - AB Science SA:

* PRESENTS PHASE 3 DATA FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS (ALS)

* ABOUT MASTINIB PHASE 3 STUDY, SAYS SAFETY WAS ACCEPTABLE WITH A POSITIVE BENEFIT-RISK BALANCE

* SAYS STUDY WAS A SUCCESS SHOWING MASITINIB TO BE A SAFE AND EFFECTIVE TREATMENT IN ALS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below